文献速递泌尿生殖与妇科肿瘤放疗

持续睾酮低下对局限期前列腺癌ADT后总生存的影响:长期前瞻性数据

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-11-23

两项随机试验中,中高危前列腺癌患者接受6、18或36个月ADT联合放疗,中位随访16.6年。睾酮恢复至正常水平者10年OS显著更高,但多因素landmark分析未显示睾酮恢复为独立预测因子。持续睾酮低下与更差生存相关,尤其老年合并症患者。

要点

  • ADT后睾酮未恢复至正常水平者10年OS显著更低(各队列P<.001)。
  • 多因素landmark分析中睾酮恢复并非OS独立预测因子。
  • 持续睾酮低下多见于年龄更大、合并症更多的患者。

核心结论

  • ADT后持续睾酮低下与更差生存相关,尤其老年合并症患者。
  • 多因素landmark分析未显示睾酮恢复为OS独立预测因子。

研究设计与样本

  • 两项随机试验的事后分析,中高危前列腺癌患者接受ADT 6、18或36个月联合放疗。
  • 中位随访16.6年,比较睾酮恢复至正常水平与未恢复者的OS。

主要发现

  • 6、18、36个月ADT队列睾酮恢复率分别为76.7%、58.6%、45.3%。
  • 中位睾酮恢复时间分别为1.64、3、5年。
  • 10年OS:恢复者vs未恢复者分别为77% vs 61%、73% vs 51%、78% vs 62%,均P<.001。

关键数值与推荐

  • 睾酮恢复定义为恢复至正常水平。
  • 多因素Cox分析纳入睾酮恢复、年龄、Zubrod体力状态、合并症、基线PSA、Gleason评分、分期和ADT duration。

临床怎么用

  • 对ADT后持续睾酮低下患者,尤其老年合并症者,应关注生存预后。
  • 睾酮恢复情况可作为风险分层参考,但不宜单独作为独立预后因子。

局限性

  • 本研究为事后分析(post hoc analysis)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The impact of persistent hypogonadism post-androgen deprivation therapy (ADT) on overall survival (OS) of patients with prostate cancer (PCa) is poorly documented. We compared OS between patients who recovered testosterone and those who did not after ADT. METHODS AND MATERIALS: Patients with PCa with intermediate- or high-risk disease were treated with ADT for 6, 18, or 36 months plus radiation therapy in 2 randomized trials. We compared OS between patients who recovered testosterone to a normal level to those who did not, using the log rank test. Multivariable Cox analysis to predict OS included recovered testosterone, age, Zubrod performance, comorbidities, baseline prostate specific antigen, Gleason score, stage, and ADT duration. To avoid immortal time bias, we performed a landmark analysis for each cohort. RESULTS: The median follow-up was 16.6 years. Patients not recovering testosterone to a normal level were older, with more associated medical comorbidities. All the results are reported respectively for the 6-, 18-, and 36-month ADT cohorts. Testosterone recovery rates, to normal level, were 76.7%, 58.6%, and 45.3% with a median time to testosterone recovery of 1.64, 3, and 5 years, respectively. The 10-year OS rates were significantly higher in patients recovering testosterone: 77% versus 61%, P < .001; 73% versus 51%, P < .001; and 78% versus 62%, P < .001. However, multivariable analyses with landmark time points failed to show testosterone recovery as an independent predictor. The study is limited by its post hoc analysis. CONCLUSIONS: In patients with PCa, our study shows that persistent hypogonadism post-ADT is associated with worse survival, particularly in older patients with medical conditions.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nabid A, Carrier N, Vigneault É, et al. Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data. Int J Radiat Oncol Biol Phys. 2025. PMID: 41275412. doi:10.1016/j.ijrobp.2025.09.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。